On October 8, the FDA gave colon cancer patients something they have never had before: an immunotherapy regimen designed to be used after surgery, when the cancer is gone but the fear isn’t.
The agency approved atezolizumab (Tecentriq, made by Genentech) together with standard chemotherapy as an adjuvant — post-surgery — treatment for Stage III mismatch repair deficient (dMMR) colon cancer. The approval covers adults and children as young as two. It also clears a subcutaneous version, Tecentriq Hybreza, for patients 12 and older, so eligible patients can get the immunotherapy as an under-the-skin injection instead of an hours-long IV infusion.
This is the first immunotherapy-based regimen approved for this setting, and Genentech expects it to become the new standard of care. That matters at scale: roughly a quarter of colon cancers are diagnosed at Stage III, and nearly one in three Stage III patients sees the cancer come back within five years.
The trial behind the approval
The decision rests on the Phase 3 ATOMIC trial, published in The New England Journal of Medicine. It enrolled 711 adults and one pediatric patient with Stage III dMMR colon cancer after complete surgical removal of the tumor. Patients got either atezolizumab plus the standard mFOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin, and fluorouracil) for 12 cycles followed by atezolizumab alone for six months — or chemotherapy alone for 12 cycles.
The headline result: the combination cut the risk of cancer returning or death by half (hazard ratio 0.50, p=0.0001). At a median follow-up of about 41 months, three-year disease-free survival hit 86.3 percent with the combination versus 76.2 percent with chemotherapy alone. The benefit held across key subgroups — node stage, tumor stage, tumor location — and in a per-protocol analysis of 600 patients.
Why dMMR tumors are immunotherapy’s best targets
A quick bit of biology makes the result click. Mismatch repair is the cell’s proofreading system — it fixes copying errors when DNA replicates. When that system is broken, mutations pile up fast, and the tumor ends up looking foreign to the immune system: covered in abnormal proteins that scream that something is wrong.
Atezolizumab is a PD-L1 inhibitor — it takes the brakes off the immune response. In a tumor already waving red flags at immune cells, releasing those brakes can be dramatic. This is precision medicine at its cleanest: instead of treating every colon cancer identically, the therapy is matched to the tumor’s biology.
Frank A. Sinicrope of the Mayo Clinic, the U.S. principal investigator for the Alliance ATOMIC trial, put the shift plainly: until now, the post-surgery standard of care did not differ based on mismatch repair status. That era is over.
What this means in practice
Three things change. First, the conversation after surgery changes — for patients whose tumors test dMMR, and testing is now more important than ever, there is a new option that halved the recurrence risk in a large randomized trial.
Second, the injection approval is a genuine quality-of-life win. Infusions consume hours of a patient’s week. A single injection is a different experience entirely, and small conveniences compound when you’re recovering from cancer surgery.
Third, this is Tecentriq’s twelfth U.S. indication. The drug keeps expanding across cancer types, and each expansion sharpens oncologists’ understanding of where immunotherapy works best.
If you or someone you love is navigating a Stage III colon cancer diagnosis, the takeaway is specific: ask whether the tumor has been tested for mismatch repair status. That single lab result now determines whether this regimen is on the table. And as always, patients already in treatment should talk to their care team before making any changes — the approval is brand new, and eligibility details matter.
Progress in cancer care rarely arrives as a single dramatic cure. More often it looks like this: a well-run trial, a 50 percent risk reduction, and thousands of families who get to breathe a little easier.
Be First to Comment